BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 34256447)

  • 1. [Preliminary clinical observation of omalizumab therapy for moderate to severe asthma].
    Wu PH; Dong C; Xie JX; Zhang XX; Liu J; Ouyang M; Ma JJ; Huang WH; Ou CX; Li J; Zhang QL
    Zhonghua Jie He He Hu Xi Za Zhi; 2021 Jul; 44(7):611-618. PubMed ID: 34256447
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efficacy of omalizumab in the treatment of eosinophilic granulomatous polyangiitis with asthma as the first symptom].
    Ou CX; Wu PH; Xie JX; Zhang XX; Ma JJ; Deng ZA; Yang XJ; Li Y; Yuan D; Xue LN; Dong C; Deng ZN; Zhang QL
    Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(34):2684-2689. PubMed ID: 36096695
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical efficacy observation of omalizumab on patients with moderate to severe allergic asthma for one year].
    Xu Y; Zhou DX; Hu P; Gong PH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Mar; 57(3):427-432. PubMed ID: 36922178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
    Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
    Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis.
    Chong W; Li H; Wang J
    Front Allergy; 2023; 4():1236798. PubMed ID: 37908372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
    Singh H; Peters JI; Kaur Y; Maselli DJ; Diaz JD
    Ann Allergy Asthma Immunol; 2019 Nov; 123(5):476-482.e1. PubMed ID: 31382020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study.
    Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
    J Asthma; 2023 Oct; 60(10):1862-1868. PubMed ID: 36971065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
    Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
    BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma.
    Pilon D; Kavati A; Ortiz B; Paknis B; Vegesna A; Schiffman B; Zhdanava M; Lefebvre P; Stone B
    Allergy Asthma Proc; 2018 Mar; 39(2):127-135. PubMed ID: 29208079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
    Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
    Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical efficacy of omalizumab for treatment of moderate or severe allergic asthma in children with serum immunoglobulin E levels >1 500 IU/mL: a prospective study].
    Luo MX; Hua S; Wei W
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Sept 15; 25(9):959-965. PubMed ID: 37718403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study.
    Barnes N; Menzies-Gow A; Mansur AH; Spencer D; Percival F; Radwan A; Niven R
    J Asthma; 2013 Jun; 50(5):529-36. PubMed ID: 23574000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of omalizumab in patients with severe allergic asthma: A retrospective study in China.
    Zhang M; Jin M; Zhou X; Lin J; Liu X; Liu C; Huang M; Wang W; Chen L; Huang Y; Li J; Zhang Q; Shen H; Yu Y; Tang W; Zhou J; Liu H; Dong L; Hu Y; Wu H; Li Y; Song W; Ouyang M; Yuan X; Wang T; Xiong S
    Respir Med; 2021 Sep; 186():106522. PubMed ID: 34229289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.
    Casale TB; Luskin AT; Busse W; Zeiger RS; Trzaskoma B; Yang M; Griffin NM; Chipps BE
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):156-164.e1. PubMed ID: 29800752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
    Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
    Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study.
    Cakmak ME; Öztop N; Yeğit OO
    Int Arch Allergy Immunol; 2024; 185(2):158-166. PubMed ID: 37992693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland.
    Jahnz-Różyk K; Lis J; Warchoł M; Kucharczyk A
    BMC Pulm Med; 2018 Mar; 18(1):48. PubMed ID: 29548318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
    Tarraf HN; Masoud HH; Zidan M; Wahba B
    J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.